Back to top

earnings-consensus: Archive

Zacks Equity Research

Performance Food Group (PFGC) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release

Performance Food (PFGC) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

PFGCPositive Net Change

Zacks Equity Research

Analysts Estimate XCel Brands (XELB) to Report a Decline in Earnings: What to Look Out for

XCel Brands (XELB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

XELBPositive Net Change ONONNegative Net Change

Zacks Equity Research

Alithya Group (ALYAF) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release

Alithya (ALYAF) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

ALYAFNegative Net Change

Zacks Equity Research

Absci Corporation (ABSI) Expected to Beat Earnings Estimates: Should You Buy?

ABSCI CORP (ABSI) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

ABSINegative Net Change IMNMNegative Net Change

Zacks Equity Research

Earnings Preview: AST SpaceMobile, Inc. (ASTS) Q2 Earnings Expected to Decline

AST SpaceMobile (ASTS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

ASTSPositive Net Change

Zacks Equity Research

Coherent (COHR) Reports Next Week: Wall Street Expects Earnings Growth

Coherent (COHR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

COHRNegative Net Change BITFPositive Net Change

Zacks Equity Research

CorMedix (CRMD) Earnings Expected to Grow: What to Know Ahead of Q2 Release

CorMedix (CRMD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

CRMDPositive Net Change KYMRPositive Net Change

Zacks Equity Research

Will ESS Tech, Inc. (GWH) Report Negative Q2 Earnings? What You Should Know

ESS Tech (GWH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

GWHNegative Net Change PLUGNegative Net Change

Zacks Equity Research

Marex Group PLC (MRX) Earnings Expected to Grow: Should You Buy?

Marex Group PLC (MRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

MRXNegative Net Change HIVEPositive Net Change

Zacks Equity Research

North American Construction (NOA) Reports Next Week: Wall Street Expects Earnings Growth

North American Construction (NOA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

NOAPositive Net Change

Zacks Equity Research

Earnings Preview: QXO, Inc. (QXO) Q2 Earnings Expected to Decline

QXO INC (QXO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

QXOPositive Net Change

Zacks Equity Research

Stantec (STN) Earnings Expected to Grow: Should You Buy?

Stantec (STN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

STNNegative Net Change

Zacks Equity Research

Earnings Preview: DLocal (DLO) Q2 Earnings Expected to Decline

DLocal (DLO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

DLONegative Net Change

Zacks Equity Research

Earnings Preview: Drilling Tools International Corp. (DTI) Q2 Earnings Expected to Decline

Drilling Tools International Corp. (DTI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

DTINegative Net Change

Zacks Equity Research

Brinker International (EAT) Earnings Expected to Grow: Should You Buy?

Brinker International (EAT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

EATNegative Net Change WENPositive Net Change

Zacks Equity Research

Wall Street Analysts Predict a 60.18% Upside in Thryv (THRY): Here's What You Should Know

The mean of analysts' price targets for Thryv (THRY) points to a 60.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

THRYNegative Net Change

Zacks Equity Research

Wall Street Analysts See a 29.42% Upside in TTM (TTMI): Can the Stock Really Move This High?

The average of price targets set by Wall Street analysts indicates a potential upside of 29.4% in TTM (TTMI). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

TTMIPositive Net Change

Zacks Equity Research

Wall Street Analysts See a 152.41% Upside in Apogee Therapeutics Inc. (APGE): Can the Stock Really Move This High?

The average of price targets set by Wall Street analysts indicates a potential upside of 152.4% in Apogee Therapeutics Inc. (APGE). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

APGENegative Net Change

Zacks Equity Research

Wall Street Analysts Think Pharming Group (PHAR) Could Surge 145.75%: Read This Before Placing a Bet

The average of price targets set by Wall Street analysts indicates a potential upside of 145.8% in Pharming Group (PHAR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

PHARPositive Net Change

Zacks Equity Research

Wall Street Analysts Believe Turtle Beach (TBCH) Could Rally 25.7%: Here's is How to Trade

The mean of analysts' price targets for Turtle Beach (TBCH) points to a 25.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

TBCHPositive Net Change

Zacks Equity Research

Earnings Preview: Madison Square Garden (MSGS) Q4 Earnings Expected to Decline

Madison Square Garden (MSGS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

MSGSNegative Net Change PRKSNegative Net Change

Zacks Equity Research

On Holding (ONON) Reports Next Week: Wall Street Expects Earnings Growth

On Holding (ONON) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

ONONNegative Net Change

Zacks Equity Research

Sky Harbour Group Corporation (SKYH) Expected to Beat Earnings Estimates: Should You Buy?

Sky Harbour Group (SKYH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

SKYHPositive Net Change MRCYPositive Net Change

Zacks Equity Research

Earnings Preview: SoundThinking (SSTI) Q2 Earnings Expected to Decline

SoundThinking (SSTI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

SSTIPositive Net Change ALRMPositive Net Change

Zacks Equity Research

Zevra Therapeutics (ZVRA) Reports Next Week: Wall Street Expects Earnings Growth

Zevra Therapeutics (ZVRA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

ZVRANegative Net Change COLLPositive Net Change